78,605 Shares in Progyny, Inc. $PGNY Purchased by OMERS ADMINISTRATION Corp

OMERS ADMINISTRATION Corp purchased a new stake in Progyny, Inc. (NASDAQ:PGNY) during the second quarter, HoldingsChannel.com reports. The firm purchased 78,605 shares of the company’s stock, valued at approximately $2,266,000.

Other large investors have also recently bought and sold shares of the company. Royal Bank of Canada lifted its position in Progyny by 384.8% during the first quarter. Royal Bank of Canada now owns 13,027 shares of the company’s stock worth $291,000 after acquiring an additional 10,340 shares during the last quarter. Amundi increased its stake in shares of Progyny by 103.8% during the first quarter. Amundi now owns 11,419 shares of the company’s stock worth $264,000 after purchasing an additional 5,817 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Progyny by 6.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 252,032 shares of the company’s stock worth $5,630,000 after purchasing an additional 14,297 shares during the period. Invesco Ltd. lifted its holdings in Progyny by 37.4% during the 2nd quarter. Invesco Ltd. now owns 379,189 shares of the company’s stock worth $8,342,000 after purchasing an additional 103,253 shares during the last quarter. Finally, Walleye Capital LLC lifted its holdings in Progyny by 6.9% during the 2nd quarter. Walleye Capital LLC now owns 12,080 shares of the company’s stock worth $266,000 after purchasing an additional 780 shares during the last quarter. 94.93% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Truist Financial upped their price objective on Progyny from $33.00 to $36.00 and gave the company a “buy” rating in a report on Thursday, August 13th. Zacks Research upgraded shares of Progyny from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, July 8th. Bank of America lifted their price objective on shares of Progyny from $29.00 to $31.00 and gave the stock a “buy” rating in a research note on Tuesday, June 2nd. Leerink Partners set a $38.00 price objective on shares of Progyny in a report on Wednesday, July 22nd. Finally, Citizens Jmp raised their target price on shares of Progyny from $30.00 to $31.00 and gave the stock a “market outperform” rating in a report on Monday, May 11th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $33.91.

Insider Activity

In other news, Director Cheryl Scott sold 7,439 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $26.39, for a total transaction of $196,315.21. Following the completion of the sale, the director owned 19,772 shares of the company’s stock, valued at approximately $521,783.08. This represents a 27.34% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Mark S. Livingston sold 2,517 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $25.50, for a total transaction of $64,183.50. Following the sale, the chief financial officer directly owned 74,688 shares of the company’s stock, valued at approximately $1,904,544. This trade represents a 3.26% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 13,563 shares of company stock valued at $351,968 in the last 90 days. 9.90% of the stock is owned by corporate insiders.

Progyny Stock Performance

NASDAQ:PGNY opened at $26.37 on Thursday. The company has a market cap of $2.02 billion, a price-to-earnings ratio of 28.66, a PEG ratio of 1.87 and a beta of 1.01. Progyny, Inc. has a fifty-two week low of $16.10 and a fifty-two week high of $33.06. The stock has a fifty day moving average price of $29.08 and a 200-day moving average price of $23.58.

Progyny (NASDAQ:PGNY) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.55 EPS for the quarter, topping analysts’ consensus estimates of $0.33 by $0.22. The company had revenue of $350.51 million for the quarter, compared to analysts’ expectations of $349.05 million. Progyny had a return on equity of 15.98% and a net margin of 6.00%.Progyny’s revenue was up 5.3% on a year-over-year basis. During the same quarter last year, the business earned $0.19 earnings per share. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. Research analysts predict that Progyny, Inc. will post 1.19 EPS for the current fiscal year.

Progyny announced that its board has authorized a stock repurchase program on Tuesday, May 26th that allows the company to buyback $200.00 million in shares. This buyback authorization allows the company to repurchase up to 10.3% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board of directors believes its shares are undervalued.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.